What is the life expectancy of someone with Smith-Lemli-Opitz Syndrome?

The life expectancy for individuals with Smith-Lemli-Opitz syndrome (SLOS) varies significantly depending on the severity of the metabolic deficiency and the presence of associated congenital anomalies. While historically associated with high infant mortality in severe cases, modern therapeutic interventions like cholesterol supplementation and multidisciplinary care have greatly improved outcomes and quality of life for many patients living with Smith-Lemli-Opitz syndrome.

How does disease severity influence the prognosis of Smith-Lemli-Opitz syndrome?

Smith-Lemli-Opitz syndrome is a spectrum disorder, meaning it ranges from mild to severe. In the most severe, classic presentations, infants may face life-threatening complications related to heart, lung, or gastrointestinal malformations. However, many individuals with milder forms of Smith-Lemli-Opitz syndrome survive well into adulthood. Prognosis is heavily influenced by how early the diagnosis is made and how effectively the body's cholesterol levels can be stabilized through clinical management. Because Smith-Lemli-Opitz syndrome is caused by a deficiency in the enzyme 7-dehydrocholesterol reductase, the resulting low cholesterol and high toxic precursors affect multiple organ systems, making the individual's unique biochemical profile a key determinant of their long-term health trajectory.

What factors affect long-term outcomes in Smith-Lemli-Opitz syndrome?

Longevity for those with Smith-Lemli-Opitz syndrome is not determined by a single factor, but rather by a combination of clinical management and biological severity. Key factors that influence the clinical course include:

• Severity of malformations: Structural issues, particularly congenital heart defects or severe gastrointestinal obstructions, are the primary drivers of early mortality.


• Metabolic stability: Consistent adherence to cholesterol supplementation protocols helps mitigate the neurological and physical symptoms of Smith-Lemli-Opitz syndrome.


• Early intervention: Access to specialized care teams—including metabolic geneticists, cardiologists, and neurologists—is essential for managing the chronic nature of Smith-Lemli-Opitz syndrome.


• Comorbidity management: Proactive treatment of secondary issues like feeding difficulties, photosensitivity, and behavioral challenges significantly enhances both life expectancy and daily functioning.

How has the outlook for Smith-Lemli-Opitz syndrome improved?

In recent decades, our understanding of the cholesterol biosynthetic pathway has transformed the management of Smith-Lemli-Opitz syndrome. While there is no cure, the standard of care now involves aggressive nutritional support and cholesterol supplementation, which can improve growth, physical strength, and neurological development. Today, many children diagnosed with Smith-Lemli-Opitz syndrome reach milestones that were previously thought impossible. For the 61 members of the DiseaseMaps.org community living with or caring for someone with Smith-Lemli-Opitz syndrome, the focus has shifted from mere survival to maximizing potential, independence, and social participation.

Is quality of life considered alongside life expectancy?

As medical experts, we emphasize that life expectancy is only one metric of a life well-lived. For individuals with Smith-Lemli-Opitz syndrome, quality of life is often shaped by the support system around them. Behavioral therapies, developmental support, and inclusive community engagement are just as vital as metabolic management. While Smith-Lemli-Opitz syndrome presents lifelong challenges, the medical community is increasingly focused on neurodevelopmental outcomes and helping patients reach their highest possible level of autonomy.

Next steps

• Consult with a board-certified metabolic geneticist to ensure your child’s cholesterol supplementation protocol is optimized.


• Engage with a multidisciplinary team, including a pediatric cardiologist and a gastroenterologist, to monitor the specific systemic impacts of Smith-Lemli-Opitz syndrome.


• Join the DiseaseMaps.org community to connect with other families navigating the complexities of Smith-Lemli-Opitz syndrome.


• Keep detailed records of developmental milestones and metabolic blood work to assist your medical team in refining long-term care goals.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Smith-Lemli-Opitz syndrome overview.


• Orphanet: Rare disease database entry for Smith-Lemli-Opitz syndrome (ORPHA:813).


• OMIM (Online Mendelian Inheritance in Man): 7-Dehydrocholesterol Reductase Deficiency; DHCR7.


• Smith-Lemli-Opitz Foundation: Patient resources and clinical research updates.